ERBIOSYS
ERBIOSYS is a Lithuania-based precision oncology bioinformatics startup focused on developing an affordable genetic breast cancer test. Their platform utilizes a proprietary AI engine to analyze multiomic molecular information (DNA, RNA, methylation, protein, phosphorylation) and a patient's medical history to create a tumor profile. This profile identifies cancer signaling pathways, evaluates drug toxicity, and analyzes drug resistance mechanisms. The company provides treatment recommendations, including conventional and unconventional therapies, referencing NCCN and ESMO guidelines, clinical trials, and academic publications. Their research areas include the use of phosphoproteomics and kynomics to understand cancer signaling and drug resistance, and bioelectricity in cancer. They aim to provide personalized therapy selection based on tumor genetics.
ERBIOSYS
ERBIOSYS is a Lithuania-based precision oncology bioinformatics startup focused on developing an affordable genetic breast cancer test. Their platform utilizes a proprietary AI engine to analyze multiomic molecular information (DNA, RNA, methylation, protein, phosphorylation) and a patient's medical history to create a tumor profile. This profile identifies cancer signaling pathways, evaluates drug toxicity, and analyzes drug resistance mechanisms. The company provides treatment recommendations, including conventional and unconventional therapies, referencing NCCN and ESMO guidelines, clinical trials, and academic publications. Their research areas include the use of phosphoproteomics and kynomics to understand cancer signaling and drug resistance, and bioelectricity in cancer. They aim to provide personalized therapy selection based on tumor genetics.